News
The day at a glance · 3 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
Kelonia Acquisition Value
>$2B
Big Pharma M&A & Pipeline Activity
Nxera Milestone Payment
$10M
Collaboration Milestones & Partnerships
Total Potential Milestones
$1.2B
Collaboration Milestones & Partnerships
Key driverMajor M&A activity and multiple FDA priority review designations signal robust pipeline momentum across large-cap pharmaceutical names
Daily briefHealthcare· Money365.Market AI ·

Eli Lilly M&A, Merck & Pfizer Win Priority Reviews

Big Pharma consolidation accelerates as FDA advances bladder cancer combination therapies; Regeneron expands into radiopharmaceuticals

Big Pharma M&A & Pipeline Activity

Neutral
LLY
Eli Lilly ($LLY) is in late-stage discussions to acquire Kelonia Therapeutics for over $2 billion, marking a significant consolidation move in the biotech sector. The deal underscores continued appetite among large-cap pharma companies to bolster pipelines through strategic acquisitions. Separately, $LLY faced regulatory challenges in India, where drug authorities seized more than 500 suspected counterfeit pens of Mounjaro, with the main accused ordering raw materials from vendors on Chinese platforms including Alibaba. The counterfeiting incident highlights ongoing supply chain and intellectual property enforcement challenges for high-value GLP-1 drugs in international markets.

FDA Priority Reviews Advance Bladder Cancer Therapies

Bullish
MRKPFE
The FDA granted priority review for Merck ($MRK) KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Padcev (enfortumab vedotin-ejfv), for cisplatin-eligible patients with muscle-invasive bladder cancer. The applications are supported by Phase 3 KEYNOTE-B15 results, which demonstrated statistically significant and clinically meaningful improvement in event-free survival. In parallel, the FDA granted priority review to a supplemental biologics license application for Pfizer ($PFE) PADCEV plus Keytruda as perioperative treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility. The submission is based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial, building on the existing indication in cisplatin-ineligible patients.

Regeneron Expands Dupixent Label & Enters Radiopharmaceuticals

Bullish
REGN
Regeneron Pharmaceuticals ($REGN) and Sanofi secured European Commission approval for Dupixent in moderate to severe chronic spontaneous urticaria for children aged 2 to 11, expanding the drug's existing label in Europe. The approval is supported by clinical data in a pediatric population with significant unmet need.
$REGN also entered a collaboration with Telix Pharmaceuticals to jointly develop and commercialize next-generation radiopharmaceutical therapies for solid tumors. The partnership brings together Regeneron's biologics expertise, including bispecific antibody capabilities, with Telix's radiopharmaceutical platform, marking Regeneron's strategic entry into the emerging radiopharmaceutical space.

Collaboration Milestones & Partnerships

Bullish

AbbVie Price Target

$260
ABBVMRNA
Nxera Pharma announced it will receive a $10 million milestone payment from AbbVie ($ABBV) under their collaboration targeting neurological diseases. This marks the third milestone achieved under the collaboration and reflects steady progress of the pipeline. Under the terms of the agreement, Nxera is eligible to receive up to $1.2 billion in potential option, development, and commercial milestones, in addition to tiered royalties based on sales.
$ABBV maintained a Buy rating from RBC Capital with a price target of $260. Meanwhile, Moderna ($MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting, with the FDA granting Fast Track designation to the combination.

MedTech & Surgical Robotics

Neutral

Stock Price

~$469+4.1%

30-Day Performance

-1.8%

YTD Performance

-16.5%

3-Year Return

+56.3%
ISRG
Intuitive Surgical ($ISRG) is scheduled to report Q1 earnings, with investors focused on robotic surgery adoption trends and competitive dynamics in the medical device space. The stock traded around $469 per share and gained 4.1% over the past week, though it has declined 1.8% over the past 30 days and is down 16.5% year-to-date. Despite near-term volatility, $ISRG has delivered strong long-term performance with a 56.3% gain over three years and 60.8% over five years. Recent headlines around robotic surgery adoption and competitive activity in medical devices have prompted investors to reassess the company's valuation ahead of the quarterly report.

Managed Care & Value Opportunities

Neutral

Royalty Pharma Q2 Dividend

$0.235
UNHGILDRPRX
UnitedHealth ($UNH) is scheduled to report Q1 earnings, providing investors with insights into managed care trends, medical cost ratios, and membership dynamics. Meanwhile, Gilead Sciences ($GILD) presents a compelling value case with strong profitability, solid financials, and a low valuation compared to biotech peers, according to analyst commentary.
Royalty Pharma ($RPRX) announced its board approved a second quarter 2026 dividend of $0.235 per Class A ordinary share, highlighting the company's cash generation model from its diversified portfolio of pharmaceutical royalties.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy